Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2015 Apr;62(4):571-6.
doi: 10.1002/pbc.25359. Epub 2014 Dec 18.

Going Back to Class I: MHC and Immunotherapies for Childhood Cancer

Free PMC article

Going Back to Class I: MHC and Immunotherapies for Childhood Cancer

Kellie B Haworth et al. Pediatr Blood Cancer. .
Free PMC article


After decades of unfulfilled promise, immunotherapies for cancer have reached a tipping point, with several FDA approved products now on the market and many more showing promise in both adult and pediatric clinical trials. Tumor cell expression of MHC class I has emerged as a potential determinant of the therapeutic success of many immunotherapy approaches. Here we review current knowledge regarding MHC class I expression in pediatric cancers including a discussion of prognostic significance, the opposing influence of MHC on T-cell versus NK-mediated therapies, and strategies to reverse or circumvent MHC down-regulation.

Keywords: MHC Class I; childhood cancers; immunotherapy.

Conflict of interest statement

The authors report no conflicts of interest.


Figure 1
Figure 1
A) NK cell interaction with antigen (Ag) on tumor cell. Both inhibitory and stimulatory ligands are shown. B) Antigen presentation to a T-cell in the context of MHC Class I. C) Chimeric Antigen Receptor (CAR). D) Bi-specific T-cell Engager (BiTE). CTL: cytotoxic T-lymphocyte, TCR: T-cell receptor, β-2-m: beta-2-microglobulin, Ag: antigen, KIR: Killer cell immunoglobulin-like receptor, scFvAb: single chain variable fragment of antibody

Similar articles

See all similar articles

Cited by 17 articles

See all "Cited by" articles

Publication types

MeSH terms